Tim Smith

This study evaluated a set of key AI outputs: skin tone representation and diagnostic accuracy of generated dermatologic diseases.

This case–control study compared sleep quality, risk of obstructive sleep apnoea, and quality of life between those with psoriasis and healthy controls.

The announcement of this NDA submission to the FDA highlights icotrokinra, a first-in-class investigational targeted oral peptide for plaque psoriasis.

This analysis examined the connection between atopic dermatitis severity and frequency of flares, along with which variables potentially predict flares.

This study highlights the impact of increased matairesinol and secoisolariciresinol consumption on gout.

This analysis highlights differences between topical and oral finasteride for hair loss, specifically looking at adverse events and any causal connections.

This July 15, 2025 SOCS News Update highlights Regine Mathieu, MD's experiences and views on collaboration opportunities.

Alopecia significantly impacts life quality, with stigma and negative perceptions contributing to mental health issues such as anxiety and depression.

This analysis suggests serum IL-13 levels are lower in bullous pemphigoid patients than in healthy controls and pemphigus vulgaris patients.

This review provides guidance to clinicians in choosing effective and safe alopecia therapies during breastfeeding periods.

This systematic review evaluated current research on dual biologic treatments in patients living with inflammatory skin conditions.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

These data resulted from a sub-study of the open-label extension (OLE) of the randomized, placebo-controlled phase 3 ‘Balance’ analysis.

This announcement highlights Pelthos Therapeutics’ launch of berdazimer (ZELSUVMI) topical gel 10.3% for molluscum contagiosum.

This study highlights the rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) use for heart failure within US ambulatory cardiovascular care settings.

These ADHAND trial data highlight the results of tralokinumab in those with atopic dermatitis on the hands who are candidates for systemic therapy.

In this session at SDPA, Griffith and Sebat review clinically relevant articles from the prior 12 months from the top dermatology journals.

These 16-week findings have been announced by Apogee Therapeutics on APG777 in patients with moderate-to-severe atopic dermatitis.

These data point to several hidradenitis suppurativa drugs as most impactful for those with moderate-to-severe disease, based on Hidradenitis Suppurativa Clinical Response.

This FDA news recap highlights some of the most notable approvals and actions by the organization in dermatology during Q2 2025.

In our recap for Q2 in dermatology, we spotlight clinical trial findings, recent updates, and advancements in different disease states.

This Month in Review summary includes a list of some of the most impactful news in the dermatology space from June 2025.

This 4-year data highlights dupilumab’s efficacy among children under the age of 12 with atopic dermatitis.

This presentation, covered at SDPA, features a discussion by Ginette Okoye, MD, who highlights diagnostic challenges among even experienced clinicians.

The topics of different hair textures and the management of alopecia in patients with skin of color were highlighted by Ginette Okoye, MD, at SDPA 2025.

This session with Ginette Okoye, MD, features a discussion about hidradenitis suppurativa (HS) and several helpful approaches for patients.

Rezpegaldesleukin showed significant efficacy in improving EASI scores in moderate-to-severe atopic dermatitis patients.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 notable dermatology updates from the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference.

This analysis highlights the risk of superficial fungal infections among patients with moderate-to-severe psoriasis given biologics such as IL-17 inhibitors.